At the IGTP TODAY
IGTP has held an event to share resources, perspectives, and advancements as a centre linked to EATRIS, with a special focus on patient involvement in biomedical research.
Researchers from five Catalan research centres have collaborated on a large-scale genetic study, identifying genetic loci and therapeutic targets that could reduce cardiovascular risk by modulating blood metabolites.
Advanced therapies and precision medicine, artificial intelligence applied to respiratory diseases, the importance of networking, or the challenges of social care and ageing in the field of research were some of the topics discussed during the 15th edition. The ICS Research Awards were also presented during the event, with the majority being awarded to female researchers this year.
The Spanish Ministry of Science, Innovation and Universities (MICIU) has awarded €1.7 million, and the European Commission an additional €466,000, to support the development of a gene therapy for Friedreich's ataxia by Biointaxis, a spin-off from IGTP.
The second CARE Workshop, held on 9-10 October, brought together more than 70 researchers from across the cancer research community at the Can Ruti Biomedical Campus for two days of scientific exchange. The event served as a platform for sharing the current cancer research being developed on the Campus and fostering stronger connections among researchers.
The organisations are collaborating on two studies in the field of severe Legionella infections and antibiotic resistance. Both projects have been presented by IGTP researchers within the framework of the "Scientific exchanges: join us" program, an initiative by Menarini to share progress and strengthen partnerships in research.
A team of researchers including the GRENBA group at IGTP has identified a promising therapy based on antimiRs to treat myotonic dystrophy type 1 (DM1). The results of their research have just been published in Science Advances.
The European Commission has granted €2,999,101 in funding to the NanoBiCar project, coordinated by Universitat Politècnica de València, with the participation of the Germans Trias i Pujol Research Institute (IGTP). The grant falls within the EIC Pathfinder Program of the European Innovation Council (EIC), a highly competitive program aimed at identifying, developing, and scaling up breakthrough technologies and disruptive innovations.
_1728469313.jpg)
The report compiles the institution's key numbers and objectives, as well as its research activities. For the first time, the report also includes a web version that summarises the most relevant aspects.
Researchers from Barcelona's Germans Trias i Pujol Institute and Josep Carreras Leukaemia Research Institute have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results, published in the Journal of Clinical Investigation, builds on two harmonized Phase I clinical trials funded by the European Union, focusing on the use of Vitamin D3 tolerogenic dendritic cells (VitD3-tolDCs) to regulate the immune response in MS patients. The team is now preparing to move into Phase II trials to further explore these findings.
